PHASE 2A STUDY OF THE PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY, INDOLENT OR AGGRESSIVE LYMPHOMA. P318, 2016: Non-Hodgkin & Hodgkin lymphoma - Novel agents

Martin Dreyling, Franck Morschhauser, Krimo Bouabdallah, David Cunningham, Dominique Bron, Kim Linton, Sarit Assouline, Gregor Verhoef, Catherine Thieblemont, Umberto Vitolo, Jose Garcia-Vargas, Igor Gorbatchevsky, Manoel Neves, Julia Grunert, Florian Hiemeyer, Barrett H Childs, Pier Luigi Zinzani

Research output: Chapter in Book/Conference proceeding › Conference contribution › peer-review

Fingerprint

Dive into the research topics of 'PHASE 2A STUDY OF THE PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY, INDOLENT OR AGGRESSIVE LYMPHOMA. P318, 2016: Non-Hodgkin & Hodgkin lymphoma - Novel agents'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry